Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析

◆英語タイトル:Dicerna Pharmaceuticals Inc (DRNA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH93530FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥78,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥117,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver such as rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Cambridge, Massachusetts, the US.

Dicerna Pharmaceuticals Inc Key Recent Developments

Apr 01,2021: Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30,2021: Dicerna’s GalXC-Plus RNAi Technology delivers target knockdown across CNS and to specific CNS cell types in preclinical studies
Mar 24,2021: Dicerna to present new GalXC-Plus nonclinical CNS data at Oligonucleotide and Precision Therapeutics Virtual Congress
Mar 05,2021: Dicerna and Roche commence Hepatitis B virus therapeutic trial

This comprehensive SWOT profile of Dicerna Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Dicerna Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Dicerna Pharmaceuticals Inc – Key Information
Dicerna Pharmaceuticals Inc – Overview
Dicerna Pharmaceuticals Inc – Key Employees
Dicerna Pharmaceuticals Inc – Key Employee Biographies
Dicerna Pharmaceuticals Inc – Key Operational Heads
Dicerna Pharmaceuticals Inc – Major Products and Services
Dicerna Pharmaceuticals Inc – History
Dicerna Pharmaceuticals Inc – Company Statement
Dicerna Pharmaceuticals Inc – Locations And Subsidiaries
Dicerna Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Dicerna Pharmaceuticals Inc – Business Description
Dicerna Pharmaceuticals Inc – Corporate Strategy
Dicerna Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Dicerna Pharmaceuticals Inc – Strengths
Dicerna Pharmaceuticals Inc – Weaknesses
Dicerna Pharmaceuticals Inc – Opportunities
Dicerna Pharmaceuticals Inc – Threats
Dicerna Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Dicerna Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Dicerna Pharmaceuticals Inc, Key Information
Dicerna Pharmaceuticals Inc, Key Ratios
Dicerna Pharmaceuticals Inc, Share Data
Dicerna Pharmaceuticals Inc, Major Products and Services
Dicerna Pharmaceuticals Inc, History
Dicerna Pharmaceuticals Inc, Key Employees
Dicerna Pharmaceuticals Inc, Key Employee Biographies
Dicerna Pharmaceuticals Inc, Key Operational Heads
Dicerna Pharmaceuticals Inc, Other Locations
Dicerna Pharmaceuticals Inc, Subsidiaries
Dicerna Pharmaceuticals Inc, Key Competitors
Dicerna Pharmaceuticals Inc, SWOT Analysis
Dicerna Pharmaceuticals Inc, Ratios based on current share price
Dicerna Pharmaceuticals Inc, Annual Ratios
Dicerna Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fazoli’s System Management, LLC:企業の戦略・SWOT・財務情報
    Fazoli’s System Management, LLC - Strategy, SWOT and Corporate Finance Report Summary Fazoli’s System Management, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Curtiss-Wright Corp (CW):石油・ガス:M&Aディール及び事業提携情報
    Summary Curtiss-Wright Corp (Curtiss-Wright) is a manufacturing and service company. It designs, manufactures, and overhauls precision components and provides highly engineered critical function products. The company also provides support services for critical applications. Curtiss-Wright serves cus …
  • Xylem Inc (XYL):石油・ガス:M&Aディール及び事業提携情報
    Summary Xylem Inc (Xylem) is a water technology company. It designs, manufactures, and services engineered solutions ranging across a wide variety of applications. The company’s offerings address customer needs across the water cycle, from the delivery, measurement and use of drinking water to the c …
  • Heron Therapeutics Inc (HRTX):医療機器:M&Aディール及び事業提携情報
    Summary Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-base …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Linde AG (LIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. It offers a wide range of compressed, liquefied gases and chemicals. It also offers engineeri …
  • Genoptix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genoptix Inc (Genoptix) is a hematopathology center which provides oncology diagnostics and informatics services specializing in hematology and solid tumors. The center offers biopharma and healthcare laboratory, discovery, drug development, care and cost development, and patient services. G …
  • Litha Healthcare Group Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Litha Healthcare Group Ltd (Litha Healthcare), formerly Myriad Medical Holdings Limited, a subsidiary of Endo International plc is a healthcare company that provides its services to public and private hospitals, pharmacies, general, allied practitioners, and government healthcare programmes. …
  • Academia Sinica-製薬・医療分野:企業M&A・提携分析
    Summary Academia Sinica is an academic institution that promotes and undertakes research activities in the disciplines of mathematics and physical sciences, life sciences, and humanities and social sciences. The institution integrates research activities to improve the planning, implementation, and …
  • Westwater Resources, Inc.:企業のM&A・事業提携・投資動向
    Westwater Resources, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Westwater Resources, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • The Avascent Group:企業の戦略・SWOT・財務情報
    The Avascent Group - Strategy, SWOT and Corporate Finance Report Summary The Avascent Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • DCS Corporation:企業の戦略・SWOT・財務情報
    DCS Corporation - Strategy, SWOT and Corporate Finance Report Summary DCS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SunOpta Inc.:企業のM&A・事業提携・投資動向
    SunOpta Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SunOpta Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Celixir Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Celixir Ltd (CTL), formerly Cell Therapy Ltd is a biotechnology company that discovers and develops regenerative medicines using adult stem cells for the treatment of heart failure. The company provids heartcel which is a type of stem cell therapy that provides improved outcomes for end-stag …
  • Southwest Gas Holdings, Inc.:企業の戦略・SWOT・財務分析
    Southwest Gas Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Southwest Gas Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Amcor Limited:企業の戦略・SWOT・財務分析
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Entertainment One Ltd.
    Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report Summary Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Public Gas Corporation SA:企業の戦略的SWOT分析
    Public Gas Corporation SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Frontken Corporation Berhad (FRONTKN):企業の財務・戦略的SWOT分析
    Summary Frontken Corporation Berhad (Frontken) is a construction and industrial equipment provider. The company’s products include valves, motors, generators, pumps, transformers, turbines, compressors, diesel engines, steel rolls and boiler tubes. It offers services including thermal spray coating, …
  • Dean Foods Co:企業のM&A・事業提携・投資動向
    Dean Foods Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dean Foods Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆